Arlington Trust »

Crispr Therapeutics shares owned by Arlington Trust

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Arlington Trust from 13F filings

Historical chart of Arlington Trust investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Arlington Trust consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Arlington Trust

Quarter filed Position value Share count Share price at filing
2024-03-31 $2.3k 34 68.15
2023-12-31 $2.1k 34 62.59

More positions owned by Arlington Trust

Vanguard High Dividend Yield ETF (VYM)
Vanguard Europe Pacific ETF (VEA)
Vanguard Dividend Appreciation ETF (VIG)
Vanguard Int High Dvd Yld In exchange traded funds (VYMI)
Microsoft Corporation (MSFT)
Schwab Strategic Tr us lrg cap etf (SCHX)
Vanguard Total Stock Market ETF (VTI)
Apple (AAPL)
Berkshire Hathaway (BRK.B)
iShares S&P 500 Value Index (IVE)
Proshares Tr russ 2000 divd (SMDV)
Spdr S&p 500 Etf (SPY)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Alphabet Inc Class A cs (GOOGL)

View all positions for Arlington Trust

Top funds holding Crispr Therapeutics

ARK Investment Management
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
Citadel Advisors
Vanguard Group
NEA Management Company
Susquehanna International
Caption Management
Bellevue Group
Credit Suisse
T. Rowe Price Associates
Bank of America Corporation
Dimensional Fund Advisors
Voloridge Investment Management
Ikarian Capital

View all funds holding Crispr Therapeutics